Q2
ABSI — Q2 2026 Financial Report Analysis
Absci's Q2 2026 net loss widened 8.6% to $33.2 million as ABS-201 trial costs lifted R&D, but a $93.6 million June offering (including $40 million from Eli Lilly) raised cash to $201.1 million and the stated runway to the second half of 2028.